View events by type

Next Generation Medical Implants - Opportunities and Challenges in Orthobiologics

  • Date(s)
    Tuesday, 20 March 2018
  • Time(s)
    Reception 6:00 PM, presentation starts at 6:30 PM
  • Venue
    Solas Building, North Campus, IT Tralee

About the event

In this presentation, Dr John Gleeson discusses next generation medical implants and the opportunities and challenges in orthobiologics.

About the speaker

Dr John Gleeson graduated in Mechanical Engineering from TCD in 2001 and completed his PhD in 2006 in the area of bone tissue disease in the Centre for Bioengineering. John joined the Tissue Engineering Research Group (TERG) at RCSI in 2006 and became a Principal Investigator (PI) and collaborator on a number of commercial implantable medical device projects, while completing an MSc in Leadership and Management part time in RCSI in 2010.

In 2012, he became a co-founder of SurgaColl Technologies Ltd which licensed his 2 technologies from the RCSI and just recently saw them translated successfully “from benchtop to beside”.

The first product, HydroxyColl, is a novel orthobiologic implant that has been implanted in 20 Irish patients and is being used in a large post market orthopaedic clinical study in the UK in 2018.

The second product, an osteochondral regeneration implant for the restoration of damaged cartilage tissue, has just recently undergone “first in human” implantations in the Santry Sports Clinic in Dublin in 2 patients. The licensed version of this osteochondral implant, known as ChondroColl, is currently undergoing regulatory approval assessment in the EU and will undergo “first in human” trials in 2018 in the UK.

John continues to be research active, with an adjunct lecturing position in RCSI and an active collaborator on a number of exciting EU H2020 projects, looking at regeneration of orthopaedic tissues and developing novel treatments for disease and injury, such as Osteoarthritis and Meniscal damage. He is a Director of SurgaColl technologies, is a member of their Scientific and Medical Advisory Board, and was previously a Board Member of the Engineers Ireland Biomedical Engineering Division Steering Committee.

His research maintains a commercial translational focus and he has extensive first-hand technical expertise in a wide range of engineering fields, as well as start-ups, MedTech regulatory approvals, intellectual property, technology translation, medical device validation and manufacturing. John has raised over €5m in start-up equity finance from both the Angel and Venture Capital community internationally and has been directly responsible for over €3m of research funding in the fields of tissue engineering and translational research.


Free - all welcome!

CPD record - 1 hour

Attendance at this event should be recorded as it can be counted as part of your overall CPD hours for the year.

Recording your CPD is really easy - visit My CPD to get started recording your 2018 CPD.